Company Overview of Novartis Pharma AG
Novartis Pharma AG provides treatments for Alzheimer’s disease, Parkinson’s disease, Attention-Deficit/Hyperactivity Disorder, epilepsy, schizophrenia, and migraine. It is also developing a treatment for type 2 diabetes; drugs therapies that improve insulin action to increase glucose disposal in the muscle, to limit its production in the liver, and to improve the kinetics of insulin secretion; and oral and physiological approach to enhancing glucagon like peptide-1 activity, which acts to stimulate insulin secretion and inhibit glucagon production. The company is based in Basel, Switzerland. Novartis Pharma AG operates as a subsidiary of Novartis AG.
41 61 324 11 11
41 61 324 80 01
Key Executives for Novartis Pharma AG
Novartis Pharma AG Key Developments
Similar Private Companies By Industry
|Acino International AG||Europe|
|AL-S Pharma AG||Europe|
|Albea Pharmaceuticals AG||Europe|
|Alpen Pharma AG||Europe|
Recent Private Companies Transactions
December 19, 2016
|Conatus Pharmaceuticals Inc.|
September 23, 2016
|BioLine Rx Ltd|
May 24, 2016
|Novartis AG,Worldwide Rights to manufacture Tekturna, Tekturna HCT, Rasilez and Rasilez HCT|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|Bloomberg L.P.||United States|
|The Advertising Council, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Novartis Pharma AG, please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.